Quantum-Si incorporated
QSIAW
NASDAQ0.20
USD
-NaN
- -
Quantum-Si incorporated
QSIAW
(NASDAQ)
Recent
price
0.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Quantum-Si Incorporated Quantum-Si Incorporated (Nasdaq: QSI) is a life sciences company that develops and commercializes next-generation protein sequencing (NGPS) platforms for single-molecule protein detection and analysis. The company offers its flagship Platinum instrument, an advanced benchtop protein sequencer providing real-time kinetic-based detection with single-amino-acid resolution; Platinum Pro, featuring enhanced data analysis, customizable user interfaces, and support for local or cloud-based processing; Platinum Analysis Software for streamlined workflows; version 4 Sequencing Kits and upcoming version 3 Library Prep Kits for low-input samples; and associated consumables including proprietary semiconductor chips. These products enable applications such as protein barcoding for multiplexed variant screening, protein identification, variant detection, post-translational modification analysis, and antibody sequencing and characterization, targeting biopharmaceutical companies, academic research institutions, clinical research organizations, and proteomics researchers in drug discovery, diagnostics, and personalized medicine. Founded in 2013 by Jonathan Rothberg and headquartered in Branford, Connecticut, Quantum-Si operates primarily in the United States with a global focus on expanding proteomics accessibility through its semiconductor-based time-domain sequencing technology, which integrates biology, chemistry, artificial intelligence, and advanced sensors to surpass traditional mass spectrometry and Edman degradation methods. In recent developments, the company achieved successful sequencing on a prototype Proteus unit in 2025, with the full platform development on track for commercialization in the second half of 2026; expanded its partnership with Planet Innovation for Proteus instrumentation development and manufacturing, building on their role as contract manufacturer for Platinum Pro set to debut in early 2025; collaborated with NVIDIA to integrate AI-driven capabilities into Proteus for enhanced data processing and biomolecule design; launched version 4 Sequencing Kits and an instrument placement program to boost academic adoption amid funding challenges; and plans to release version 3 Library Prep Kits by year-end 2025 while highlighting Proteus advancements at its November 2025 Investor and Analyst Day.
Quantum-Si (NASDAQ:QSIAW) Trading Down 5.8% – Should You Sell?
Quantum-Si (NASDAQ:QSIAW) Trading 13.4% Higher – Here’s Why